Bioisosteric modification of salvinorin A, a potent and selective kappa-opioid receptor agonist

Arzneimittel-Forschung/Drug Research

Volumn 56, Issue 4, 2006, Pages 269-275

  Stewart, D Jeremy ^a   Fahmy, Hesham ^a   Roth, Bryan L ^b   Yan, Feng ^b   Zjawiony, Jordan K ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CAS 83729 01 5; Kappa opioid receptor agonist; Salvia divinorum; Salvinorin A

Indexed keywords

CALCIUM; CARBONYL DERIVATIVE; KAPPA OPIATE RECEPTOR; NITROGEN; SALVINORIN A; THIOACETIC ACID;

ARTICLE; BINDING AFFINITY; CALCIUM CELL LEVEL; DRUG ISOLATION; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL;

EID: 33646421942     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296720     Document Type: Article

References (24)

1. Ortega, A., Blount, J. F., Manchand, P. S., Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum (Labiatae), J. Chem. Soc., Perkin Trans, 1 10, 2505 (1982)
2. Valdes III, L. J., Butler, W. M., Hatfield, G. M., et al., Divinorin A, a psychotropic terpenoid, and divinorin B from the hallucinogenic Mexican mint Salvia divinorum. J. Org. Chem. 49, 4716 (1984)
3. Roth, B. L., Baner, K., Westkaemper, R. et al., Salvinorin A: A potent naturally occurring non-nitrogenous κ-opioid selective agonist. Proc. Natl. Acad. Sci. 99, 11934 (2002)
4. Chavkin, C., Sud, S., Wenzhen, J. et al., Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum, is a highly efficacious kappa opioid receptor agonist: Structural and functional considerations. J. Pharmacol. Exp. Ther. 308, 1197 (2004)
5. Siebert, D. J., Salvia divinorum and salvinorin A: New pharmacological findings. J. Ethnopharmacol. 43, 53 (1994)
6. Bohn, L. M., Belcheva, M. M., Coscia, C. J., Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells; evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade. J. Neurochem. 74, 564 (2000)
7. Pan, E. C., Bohn, L. M., Belcheva, M. M. et al., Kappa-opioid receptor binding varies inversely with tumor grade in human gliomas. Cancer 83, 2561 (1998)
8. Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., et al., Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. 305, 323 (2003)
9. Hanes, K. R., Antidepressant effects of the herb Salvia divinorum: A case report. J. Clin. Psychopharmacol. 21, 634 (2001)
10. Shippenberg, T. S., Chefer, V. I., Zapata, A. et al., Modulation of the behavioral and neurochemical effects of psychostimulants by κ-opioid receptor systems. Ann. N. Y. Acad. Sci. 937, 50 (2001)
11. Zhang, Y., Butelman, E. R., Schlussman, S. D. et al., Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacol. 179, 551 (2005)
12. Smith, M. A., Bryant, P. A., McClean, J. M., Social and environmental enrichment enhances sensitivity to the effects of kappa opioids: studies on antinociception, diuresis, and conditioned place preference. Pharm. Biochem. Behav. 76, 93 (2003)
13. Boyle, T. J., Masuda, T., Cunningham, S. T., Effects of a kappa agonist, spiradoline mesylate (U62, 066E), on activation and vaginocervical-stimulation produced analgesia in rats. Brain Res Bull. 54, 213 (2001)
14. Simonato, M., Romualdi, P., Dynorphin and epilepsy. Prog. Neurobiol. 50, 557 (1996)
15. Tortella, F. C., Echevarria, E., Lipowski, A. W. et al., Selective kappa antagonist properties of nor-binaltorphimine in the rat MES seizure model. Life Sci. 44, 661 (1989)
16. Chen, T. Y., Goyagi, T., Toung, T. J. et al., Prolonged opportunity for ischemic neuroprotection with selective kappa-opioid receptor agonist in rats. Stroke 35, 1180 (2004)
17. Wang, J. Q., Ingenito, A. J., Comparative effects of intrahippocampal injection of dynorphin A(1-8), dynorphin A(1-13), dynorphin A(1-17), U-50488H, and dynorphin B on blood pressure and heart rate in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Peptides 15, 125 (1994)
18. Ventura, C., Guarnieri, C., Vaona, I. et al., Dynorphin gene expression and release in the myocardial cell. J. Biol. Chem. 269, 5384 (1994)
19. Walsh, S. L., Strain, E. C., Abreu, M. E. et al., Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacol. 157, 151 (2001)
20. Wadenberg, M. L., A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist CNS Drug Rev. 9, 187 (2003)
21. Butelman, E. R., Harris, T. J., Kreek, M. J., The plant-derived hallucinogen, salvinorin A produces κ-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacol. 172, 220 (2004)
22. Munro, T. A., Rizzacasa, M. A., Roth, B. L. et al., Studies toward the pharmacophore of salvinorin A, a potent κ-opioid receptor agonist. J. Med. Chem. 48, 345 (2005)
23. Stewart, D. J., Phytochemical Investigation of Salvia divinorum. Ph.D. Thesis, pp. 59 and 73. University of Mississippi, University, MS (2005)
24. Lee, D. Y., Karnati, V. V., He, M. et al., Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues. Bioorg. Med. Chem. Lett. 15, 3744 (2005)